Clinical Outcomes and Management of Small Bowel Adenocarcinoma

Small bowel adenocarcinoma is a rare malignancy arising in the duodenum, jejunum or ileum, accounting for fewer than 5 per cent of gastrointestinal cancers. Patients often present with non-specific symptoms such as abdominal pain, weight loss or gastrointestinal bleeding, leading to delayed diagnosis and advanced stage at presentation. Surgical resection remains the cornerstone of curative treatment, with segmental resection or pancreaticoduodenectomy employed according to tumour location. Despite improvements in imaging and endoscopic techniques, over 60 per cent of cases are detected at stage III or IV, where five-year overall survival falls below 30 per cent. Adjuvant chemotherapy regimens modelled on colorectal protocols yield modest benefit, although evidence remains inconclusive. Recent advances in molecular profiling have unveiled recurrent mutations in TP53, KRAS and SMAD4, along with novel driver genes such as SOX9 and ACVR2A, opening avenues for targeted therapies. Prognostic factors include tumour stage, nodal involvement and histopathological grade. Global trends indicate a rising incidence linked to lifestyle and metabolic risk factors, underscoring the need for preventive strategies and earlier detection. Multidisciplinary care integrating surgical, medical and endoscopic expertise is essential to improve outcomes and quality of life.

Research from Nature Portfolio

A seminal prognostic study developed and externally validated a nomogram for postoperative survival in duodenal adenocarcinoma patients. Age, tumour grade and tumour–node–metastasis stage emerged as independent predictors of cancer-specific survival. The nomogram demonstrated superior discriminatory accuracy compared with conventional staging, offering personalised risk stratification and guiding decision-making on adjuvant therapy. External validation in an independent cohort confirmed its robustness, suggesting a new standard for prognostic assessment in small bowel adenocarcinoma.

Clinical Outcomes and Management of Small Bowel Adenocarcinoma publication trend

The graph below shows the total number of articles in clinical outcomes and management of small bowel adenocarcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival: The proportion of patients alive for a specified period after diagnosis or treatment.

Disease-specific survival: The proportion of patients not dying from the cancer of interest over a defined time.

Nomogram: A statistical tool that predicts individual patient outcomes by integrating multiple prognostic variables.

Adjuvant therapy: Treatment given after primary surgery to eradicate microscopic disease and reduce recurrence risk.

Tumour–node–metastasis (TNM) staging: A classification system describing tumour size, regional lymph node involvement and distant spread.

References

1. Prognosis and nomogram for predicting postoperative survival of duodenal adenocarcinoma: A retrospective study in China and the SEER database. Scientific Reports (2018).
2. Clinicopathological features and prognosis of primary small bowel adenocarcinoma: a large multicenter analysis of the JSCCR database in Japan. Journal of Gastroenterology (2024).
3. Incidence, Risk Factors, and Temporal Trends of Small Intestinal Cancer: A Global Analysis of Cancer Registries. Gastroenterology (2023).
4. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLOS Genetics (2018).
5. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget (2015).